

**Identification of common genetic variants  
influencing spontaneous dizygotic twinning  
and female fertility**

Hamdi Mbarek,<sup>1,21,\*</sup> Stacy Steinberg,<sup>2,22</sup> Dale R. Nyholt,<sup>3,4,22</sup> Scott D. Gordon,<sup>4</sup> Michael B. Miller,<sup>5</sup> Allan F. McRae,<sup>6,4</sup> Jouke Jan Hottenga,<sup>1,21</sup> Felix R. Day,<sup>20</sup> Gonneke Willemsen,<sup>1,21</sup> Eco J. de Geus,<sup>1,21</sup> Gareth E. Davies,<sup>7</sup> Hilary C. Martin,<sup>8</sup> Brenda W. Penninx,<sup>9</sup> Rick Jansen,<sup>9</sup> Kerrie McAloney,<sup>4</sup> Jacqueline M. Vink,<sup>1</sup> Jaakko Kaprio,<sup>10</sup> Robert Plomin,<sup>11</sup> Tim D. Spector,<sup>12</sup> Patrik K. Magnusson,<sup>13</sup> Bruno Reversade,<sup>14</sup> R. Alan Harris,<sup>15</sup> Kjersti Aagaard,<sup>15</sup> Ragnar P. Kristjansson,<sup>2</sup> Isleifur Olafsson,<sup>16</sup> Gudmundur Ingi Eyjolfsson,<sup>17</sup> Olof Sigurdardottir,<sup>18</sup> William G. Iacono,<sup>5</sup> Cornelis B. Lambalk,<sup>19</sup> Grant W. Montgomery,<sup>4</sup> Matt McGue,<sup>5</sup> Ken K. Ong,<sup>20</sup> John R.B Perry,<sup>20</sup> Nicholas G. Martin,<sup>4</sup> Hreinn Stefánsson,<sup>2</sup> Kari Stefánsson,<sup>2</sup> and Dorret I. Boomsma,<sup>1,21,\*</sup>

<sup>1</sup>Department of Biological Psychology, [Vrije U-Amsterdamniversiteit](https://www.vrije-amsterdam.nl), 1081BT Amsterdam, The Netherlands.

<sup>2</sup>deCODE Genetics, 101 Reykjavik, Iceland.

<sup>3</sup>Institute of Health and Biomedical Innovation, Queensland University of Technology, 4059 Brisbane, Australia.

<sup>4</sup>QIMR Berghofer Medical Research Institute, 4029 Brisbane, Australia.

<sup>5</sup>Department of Psychology, University of Minnesota, Minneapolis, MN 55455, USA.

<sup>6</sup>Queensland Brain Institute, The University of Queensland, 4072 Brisbane, Australia.

<sup>7</sup>Avera Institute for Human Genetics, Sioux Falls, SD 57108, USA.

<sup>8</sup>Wellcome Trust Centre for Human Genetics, OX3 TBN Oxford, United Kingdom.

<sup>9</sup>Department of Psychiatry and EMGO Institute for Health and Care Research, [Vrije U Universiteity](https://www.vrije-amsterdam.nl), Medical Center/GGZ inGeest, 1081HL Amsterdam, The Netherlands.

<sup>10</sup>Institute for Molecular Medicine Finland FIMM, University of Helsinki; Department of Public Health, University of Helsinki; National Institute for Health and Welfare, FI-00014 Helsinki, Finland.

<sup>11</sup>Medical Research Council Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF London, United Kingdom.

<sup>12</sup>Department of Twin Research & Genetic Epidemiology, King's College London, SE1 7EH London, United Kingdom.

<sup>13</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden.

<sup>14</sup>Institute of Medical Biology, A\*STAR, 138648 Singapore, Singapore.

<sup>15</sup>Division of Maternal-Fetal Medicine, Departments of Obstetrics and Gynecology, Molecular and Human Genetics, and Molecular and Cell Biology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX 77030, USA.

<sup>16</sup>Department of Clinical Biochemistry, Landspítali- The National University Hospital of Iceland, 101 Reykjavik, Iceland.

<sup>17</sup>Icelandic Medical Center (Laeknasetrid), Laboratory in Mjodd (RAM), Reykjavik, Iceland.

<sup>18</sup>Department of Clinical Biochemistry, Akureyri Hospital, 109 Akureyri, Iceland.

<sup>19</sup>Department of Obstetrics, Gynecology and Reproductive Medicine, VU University Medical Center, 1007MB Amsterdam, The Netherlands.

<sup>20</sup>MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, CB2 0QQ Cambridge, United Kingdom.

<sup>21</sup>EMGO+ Institute for Health and Care Research, 1081BT Amsterdam, The Netherlands.

<sup>22</sup>These authors contributed equally to this study

\*Correspondence to [h.mbarek@vu.nl](mailto:h.mbarek@vu.nl) (H.M, @drHamdiMbarek), [di.boomsma@vu.nl](mailto:di.boomsma@vu.nl) (D.I.B)

## Abstract

Spontaneous dizygotic (DZ) twinning occurs in 1-4% of women, with familial clustering and unknown ~~patho~~physiological pathways and genetic origin. DZ twinning may index increased fertility and has distinct health implications for mother and child. We performed ~~the first a~~ GWA study in 1,980 mothers of spontaneous DZ twins and 12,953 controls. Findings were replicated in a large Icelandic cohort and tested for association across a broad range of fertility traits in women. Two SNPs were identified (rs11031006 near *FSHB*,  $p = 1.54 \times 10^{-9}$ , and rs17293443 in *SMAD3*,  $p = 1.57 \times 10^{-8}$ ) and replicated ( $p = 3 \times 10^{-3}$  and  $p = 1.44 \times 10^{-4}$ , respectively). Based on ~90,000 births in Iceland, the relative risk of a mother delivering twins increased by 18% for each copy of ~~the allele~~ rs11031006-G, and 9% for ~~the~~ rs17293443-C. A higher polygenic risk score (PRS) for DZ twinning, calculated based on the results of the DZ twinning GWAS, was significantly associated with DZ twinning in Iceland ( $p = 0.001$ ). A higher PRS was also associated with having children ( $p = 0.01$ ), greater lifetime parity ( $p = 0.03$ ) and earlier age at first child ( $p = 0.02$ ). ~~The Allele~~ rs11031006-G was associated with higher serum FSH levels, earlier age at menarche, earlier age at first child, higher lifetime parity, lower PCOS risk, and earlier age at menopause. Conversely, ~~the~~ rs17293443-C was associated with later age at last child. We identified ~~the first~~ robust genetic risk variants for DZ twinning: one near *FSHB*, and a second within *SMAD3*, ~~—~~the product of which plays an important role in gonadal responsiveness to FSH. These loci contribute to crucial aspects of reproductive capacity and health.

## 1 **Introduction**

2 DZ twinning (MIM: 276400) is defined as the concomitant conception and  
3 development of two independent zygotes during one pregnancy. Mothers of spontaneous  
4 (conceived without assisted reproductive technology) DZ twins have a predisposition to  
5 multiple ovulation events due to interference with single dominant follicle selection, a  
6 biological mechanism fundamental for the human species.<sup>1</sup> DZ twinning is common, with  
7 large regional differences from six per 1000 births in Asia to 40 per 1000 births in Africa,<sup>2</sup>  
8 whereas monozygotic twinning occurs around the world at a constant rate of around three to  
9 four per 1000 births.<sup>3; 4</sup> DZ twinning rates also vary substantially over time. For example, in  
10 the US, the observed incidence of twin births increased by a factor of 1.9 between 1971 and  
11 2009.<sup>5</sup> While a considerable part of the increase is attributable to fertility treatments, with an  
12 estimate of 36% of all twins born in the USA in 2011 resulting from assisted reproduction, the  
13 majority of twins are still conceived spontaneously. In addition to fertility treatments,  
14 increases in maternal age contribute to increases in twinning incidence.<sup>3; 6</sup>

15 Twinning is associated with increased risks to mother and offspring, including higher  
16 risks of stillbirth, neonatal death and premature birth. Compared to singleton children, twins  
17 use more hospital resources, especially during the first year of life,<sup>7</sup> with hospital costs in the  
18 first five years of life being as much as 3-3-fold higher.<sup>8</sup>

19 Mothers of DZ twins differ from other women in that they are taller, have an increased  
20 BMI, are more often overweight and more often smoke before the twin pregnancy.<sup>9</sup> Family  
21 history, increased parity and gravidity all increase the risk of spontaneous DZ twinning.<sup>1; 3</sup>  
22 Remarkably, twinning rates do not reflect average nutritional status of a population, as  
23 established from longitudinal studies in countries that experienced periods of starvation, such  
24 as the Dutch hunger winter. Above a specific, yet undetermined, threshold, nutrition seems to  
25 be of minimal importance for reproduction in general and also for twinning.<sup>10</sup> These

26 observations all point to spontaneous twinning being a heritable trait and suggest the potential  
27 for polygenic inheritance. In a landmark study of twinning based on data from genealogic  
28 records from Utah,<sup>11</sup> White and Wyshak established that the genotype of the mother, but not  
29 that of the father, affects the frequency of DZ twinning.

30         The underlying physiological mechanism for DZ twinning is the release and  
31 fertilization of two or more oocytes. Ovarian folliculogenesis and determination of ovulation  
32 quota are controlled both by circulating concentrations of follicle-stimulating hormone (FSH)  
33 and by intra-ovarian factors including the two oocyte growth factors, *GDF9* (MIM: 601918)  
34 and *BMP15* (MIM: 300247), as well as their cognate receptors.<sup>12</sup> In the common marmoset  
35 monkey (subfamily Callitrichinae), DZ twins comprise the predominant litter size, and  
36 singletons are rarely, if ever, observed. On DNA sequencing, specific nonsynonymous  
37 substitutions were identified in *GDF9*, *BMP15*, *BMP4* (MIM: 112262), and *WFIKKN1* (MIM:  
38 608021) as having a role in Callitrichine twinning.<sup>13</sup> These genes are among a larger set of 63  
39 candidate genes with a potential involvement in regulation of ovulation number and/or control  
40 of growth and body size.<sup>14</sup>

41         Efforts to characterize the genes that contribute to DZ twinning in humans have not  
42 been successful. Candidate gene and genome-wide linkage studies failed to uncover common  
43 variants associated with DZ twinning,<sup>15-19</sup> although one study reported rare variants in *GDF9*  
44 to be associated with DZ twinning.<sup>18</sup>

45         DZ twinning has been suggested as a measure of human fertility both at the individual  
46 and at the population level.<sup>20</sup> Spontaneous DZ twinning may be considered as a marker of  
47 high fertility, as it reflects the frequency of double ovulation, the probability of coitus within  
48 the appropriate time frame with fertilization of both ova, and maintenance of a multiple  
49 pregnancy.

50 | The aim of this study was to perform ~~the first a~~ genome-wide association study  
51 | [\(GWAS\)](#) in mothers of spontaneous DZ twins to identify relevant genomic regions and test  
52 | their significance across a broad range of female fertility and reproductive traits including age  
53 | at menarche, age at natural menopause, age at first and last child, and lifetime parity. [Three](#)  
54 | [twin registries, from the Netherlands, Australia and Minnesota \(USA\) had detailed](#)  
55 | [information on spontaneous twinning in mothers of DZ twins, as well as genotype data.](#)  
56 | [Replication of top hits for twinning was possible in the Icelandic population and for other](#)  
57 | [measures of reproductive ageing in several large-scale population meta-analyses](#)<sup>21-24</sup> .  
58 |

## 59 | **Material and Methods**

60 | ~~Details of methods and associated references can be found in the supplemental data.~~

### 61 | **Descriptions of Participating Studies**

#### 62 | *Netherlands Twin Register (NTR)*

63 | [The NTR sample consisted of 806 cases and 4,535 controls from the Netherlands Twin](#)  
64 | [Register \(2,776 participants\) and the Netherlands Study of Depression and anxiety \(NESDA;](#)  
65 | [2,565 participants\). NTR participants were ascertained by the presence of liveborn twins or](#)  
66 | [triplets in the family and consist of multiples, their parents, siblings and spouses. Twins were](#)  
67 | [born in all strata of society and NTR represents a general sample from the Dutch population](#)<sup>25-</sup>  
68 | <sup>28</sup> [. NESDA is a longitudinal study focusing on the course and consequences of depression and](#)  
69 | [anxiety disorders. Subjects for NESDA were recruited from the general population, mental](#)  
70 | [health organizations and general practices. The sample includes subjects selected for](#)  
71 | [depression and anxiety, as well as healthy controls](#)<sup>29</sup> . [Zygosity of twins was confirmed by](#)  
72 | [DNA genotyping. Data on mode of pregnancy were available from several data collection](#)  
73 | [waves including surveys sent out to mothers of twins, a survey to parents upon registration of](#)  
74 | [young twins, and telephone interview as part of a project on DZ twinning](#)<sup>9</sup> . The comparison of

75 the survey data with the hospital records showed that mothers can accurately report on the  
76 mode of conception of their twins<sup>30</sup>. Participants were excluded if they reported the use of  
77 assisted reproductive technology at one or more occasions. In case no reports on mode of  
78 pregnancy were available, data were excluded unless the twins were born prior to 1985.  
79 *QIMR Berghofer Medical Research Institute (QIMR)*  
80 The sample used in this analysis consisted of 606 cases and 6,656 controls. The individuals  
81 were drawn from families containing (any type of) twins recruited for prior studies, either  
82 from around Australia from the Australian Twin Registry (ATR) (generally twins born before  
83 1971) or from south-eastern Queensland (generally twins born after 1980). Study recruitment  
84 was predominantly population based (any family where the twins were willing to participate)  
85 with no screening performed on reproductive phenotypes apart from selecting families with  
86 twins. Studies for the older cohort typically were focused on personality traits but not selected  
87 for them. Zygosity of twins was reported at time of recruitment; during phenotyping studies;  
88 and tested by genotyping (on SNP arrays or Sequenom assays). New phenotyping excluded  
89 mothers ('cases') from Queensland cohort, who used Assisted Reproductive Technology  
90 (ART—typically IVF or hormone treatment) to become pregnant. Screening questions asked of  
91 the mother during clinical sessions for phenotyping, were the primary basis for excluding  
92 ART cases. A smaller subset of mothers was contacted specifically to establish this  
93 information where it was not otherwise available. For the older (ATR) cohort, at the time of  
94 the twins' birth, IVF was not yet in clinical use and other ART was rare.  
95 *Minnesota Center for Twin and Family Research (MCTFR)*  
96 All subjects in this sample were independently ascertained through vital records of the State  
97 of Minnesota in an effort to construct a population-based twin registry<sup>31; 32</sup>. The sample for  
98 the current study consisted of 568 mothers of DZ twins and 1,862 controls who were the  
99 parents of MZ twins from 1,062 families, including 800 complete parental pairs, 203 mothers

100 [and 59 fathers. Most of the twins were born in the 70s or early 80s, when even though fertility](#)  
101 [treatment was available in the US, it was expensive and few had access to it. Genotyping was](#)  
102 [population-based and independent of phenotypes other than twinning. About 92% of the](#)  
103 [registry, and 100% of both case and control samples, are of primarily European ancestry.](#)  
104 [Iceland \(deCODE\)](#)  
105 [Mothers of twins or other multiples \(“twins”\) were selected from among those taking part in](#)  
106 [deCODE’s genetic studies based on a nationwide genealogical database. To increase the](#)  
107 [proportion of these mother of twins who were mothers of dizygotic twins, twins who had been](#)  
108 [genotyped and shown to be monozygotic were not used to identify mothers. Controls were](#)  
109 [individuals participating in deCODE’s genetic research from which both mothers of twins and](#)  
110 [the mothers’ first-degree relatives had been removed. For the prediction of twinning using](#)  
111 [polygenic risk scores, mothers having opposite sex or verified dizygotic twins were compared](#)  
112 [with mothers who did not have twins.](#)

#### 114 **Study Design, Genome-Wide Association Study and Replication**

115 We established the Twinning GWAS Consortium (TGC) to characterize the genetic basis of  
116 DZ twinning in humans and performed [the first a](#) genome-wide association study (GWAS)  
117 for DZ twinning utilizing [data from](#) 1,980 mothers of DZ twins (MODZT) and 12,953  
118 controls from ~~The Netherlands, US and Australian~~ European ancestry cohorts. Sample sizes  
119 and study characteristics are described in table [S1](#). All cases underwent screening to exclude  
120 mothers who received assisted reproductive techniques. Controls were screened to exclude  
121 pedigrees containing DZ twins. In the replication stage, significant findings from the meta-  
122 analysis were tested in large Icelandic cohort of 3,597 mothers of twins and 297,348 controls.  
123 All participants provided written informed consent, including consent for genotyping and



124 analysis, [and were recruited according to the protocols approved by the institution review](#)  
125 [board of each institution.](#)

## 127 **Fertility Traits Measures**

128 Fertility measures (having children, number of children, age at first and last child and average  
129 birth interval) were defined in females born before 1970 based on the Icelandic genealogy.  
130 [Data for age at menarche, age at menopause and polycystic ovary syndrome were derived](#)  
131 [from previously published GWAS consortia<sup>21-24</sup>. Sample sizes and study characteristics are](#)  
132 [described in table 2.](#)

## 134 **Genotyping, Quality Control and Imputation**

135 Each participating cohort performed participant-level genotyping of single nucleotide  
136 polymorphisms (SNPs), that included standard quality-control measures for genotyping and  
137 imputation (Table S21 [and Supplemental Methods](#)). All imputations were performed using the  
138 1000 Genomes Project March 2012 release as the reference panel.

## 139 **Statistical analysis**

140 ~~GWA analysis was performed in each cohort using logistic regression under an additive~~  
141 ~~genetic model with adjustment for principal components of genetic ancestry and specific~~  
142 ~~covariates for each study. GWA results for each SNP (odds ratio [OR] and 95% confidence~~  
143 ~~interval [CI]) were combined across cohorts using fixed-effect meta-analysis with inverse~~  
144 ~~variance weighting. The most significant SNP at each genome-wide significant ( $p < 5 \times 10^{-8}$ )~~  
145 ~~locus was tested in the replication stage and replicating SNPs were examined for association~~  
146 ~~with FSH levels and other fertility traits.~~

## 147 **Association Tests**

148 Each genome-wide association analysis from the three cohorts was conducted using logistic  
149 regression under an additive genetic model with adjustment for principal components of  
150 genetic ancestry. Because the GWAS data include family members we added the –family  
151 option in the analysis, which takes the familial structure of the data into account using a  
152 sandwich estimator<sup>33</sup>. Imputed SNPs were analyzed using PLINK software<sup>34</sup> and genotype  
153 imputation uncertainty was accounted for by using allelic dosage in PLINK.  
154 Meta-analysis was performed using the fixed-effects inverse variance method based on the  
155 regression  $\beta$  estimates and standard errors from each study implemented in METAL<sup>35</sup>. The  
156 presence of heterogeneity between cohorts for the effect sizes of risk alleles was investigated  
157 using the Cochran’s  $Q$ -test as implemented in METAL. To determine whether the genome-  
158 wide significant signal at each locus with low LD in the same chromosomal region (defined  
159 as  $r^2 < 0.05$  in a 750-kb region) could be accounted for by a single SNP, we carried out  
160 conditional analysis. Each cohort performed a genome-wide analysis for MODZT using  
161 logistic regression adjusting for the top signal at each of the three associated regions to  
162 determine whether potential second signals remained significant even after adjusting for these  
163 variants. Results from each individual study were meta-analyzed to determine whether these  
164 potential second signals were truly independent (that is, if  $p < 5 \times 10^{-8}$ ). In Iceland, being a  
165 mother of twins was tested for association with the top alleles using logistic regression and  
166 including age, age-squared and county of birth as covariates as described previously<sup>36</sup>.  
167 Associations between FSH level and genotype was assessed using linear regression as  
168 described previously<sup>36</sup>. To study the association of fertility measures and SNP genotype, we  
169 used logistic regression (having children), Poisson log-linear regression (number of children),  
170 or linear regression (age at first child, age at last child, and average birth interval). In these  
171 analyses, birth cohort (as a factor for each five year interval), county of birth and six principal  
172 components were included as covariates. Relatedness was controlled for by using genomic

173 [control in all Icelandic association analyses](#)<sup>37</sup>. [The combined p value of the meta-analysis and](#)  
174 [the replication study was calculated using Fisher's combined probability test](#)<sup>38</sup>.

### 176 **FSH Serum Level Measure**

177 [Serum levels of follicle-stimulating hormone \(FSH\) were measured in 2,411 men \(1,275](#)  
178 [genotyped persons; 1,136 close relatives of genotyped individuals\) and 15,586 women \(9,738](#)  
179 [genotyped persons; 5,848 close relatives of genotyped individuals\) referred to three clinics in](#)  
180 [Iceland. FSH testing was undertaken primarily to investigate possible gonad impairment.](#)  
181 [Hormone levels were measured by electrochemiluminescence immunoassay, using reagents](#)  
182 [and analytical instruments from Roche Diagnostics GmbH, according to the manufacturer's](#)  
183 [instructions.](#)

### 185 **In silico Functional Annotation**

186 [We used a number of publicly available bioinformatics tools and datasets to identify putative](#)  
187 [functional effects of the top associated SNPs at each locus, including: Combined Annotation](#)  
188 [Dependent Depletion \(CADD\)<sup>39</sup>, HaploReg2 v4<sup>40</sup> and Variant effect predictor \(VEP\)<sup>41</sup>.](#)

### 190 **Gene Based Test**

191 [Results of the MODZT meta-analysis were used to perform a gene-based test of association](#)  
192 [for the 63 candidate genes from Harris et al. using the \*Knowledge-based mining system for\*](#)  
193 [Genome-wide Genetic studies \(KGG\) software Version 3.5<sup>42; 43</sup>. This approach uses an](#)  
194 [extended Simes test that integrates prior functional information and the meta-analysis](#)  
195 [association results when combining the SNP p values within a gene in order to obtain an](#)  
196 [overall association p value for each entire gene. As we tested for genetic association for 63](#)  
197 [genes, the significance level was set at  \$7.93 \times 10^{-4}\$  \(Bonferroni correction; 0.05/63\).](#)

198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222

### [Polygenic Risk Scores \(PRS\)](#)

[Polygenic risk scores were calculated based on the results of the MODZT meta-analysis. Only markers having  \$info > 0.9\$  in all groups and  \$MAF > 0.01\$  were included. To obtain effect sizes taking LD into account, the LDpred method developed by Vilhjálmsson and colleagues was used<sup>44</sup>. As suggested by Vilhjálmsson et al, we calculated multiple sets of LD-modified effect sizes based on a grid of values for the fraction of causal markers \( \$\alpha = 0.0001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1\$ \). The resulting scores were then tested in a validation data set of Icelandic mothers of dizygotic twins. The score producing the most significant result in the validation data set were subsequently used to test for association with five fertility-related traits \(“has children”, “number of children”, “age at first child”, “age at last child” and “average birth interval”\).](#)

## **Results**

### **Genome-wide association results, replication and gene based analyses**

The overall GWAS meta-analysis genomic control statistic ( $\lambda$ ) was 1.01, indicating no appreciable inflation due to population structure. The quantile-quantile (Q-Q) plot of genome-wide p values showed a strong deviation from the null hypothesis of no association (Figure S1). The results are represented in the Manhattan plot (Figure 1). Three chromosomal regions contained genome-wide significant SNPs ( $p < 5 \times 10^{-8}$ ). Twenty-two SNPs on chromosome 11p13 showed genome-wide significant associations. Of these, the strongest signal (rs11031006,  $p = 1.54 \times 10^{-9}$  and OR 1.41, 95% CI 1.29-1.53) lies in the region 5' of the transcription start site of *FSHB* (encoding the FSH, beta polypeptide, [MIM: 136530]). A second locus was represented by five SNPs on *Iq42.13* covering an intergenic region flanked by *PGBD5* (MIM: 616791) and *COG2* (MIM: 606974), ( $p = 1.23 \times 10^{-8}$ , OR 1.43, 95% CI

223 1.31-1.55 for strongest signal, rs12064669). A third locus on *15q22.33*, mapped to the first  
224 intron of *SMAD3* (SMAD family member 3, [MIM: 603109]) (rs17293443,  $p = 1.57 \times 10^{-8}$   
225 and OR 1.27, 95% CI 1.19-1.35). [No significant heterogeneity in SNP effects was observed](#)  
226 [across cohorts for the top SNPs \( \$p > 0.1\$ , Cochran's  \$Q\$  test\); Tables \[43\]\(#\) and \[S23\]\(#\)\). The  
227 regional association plots for these loci are shown in figure S2. After conditioning on the top  
228 SNPs at each locus, no secondary signals were observed \(all  \$p > 0.05\$ ; Tables \[S43\]\(#\), \[S54\]\(#\) and  
229 \[S65\]\(#\)\). We sought validation of these three top signals in an independent replication study from  
230 Iceland \(deCODE\) totaling 3,597 mothers of twins and 297,348 controls. The \*FSHB\*  
231 \(rs11031006,  \$p = 3 \times 10^{-3}\$ , OR 1.14, 95% CI 1.06-1.22\) and \*SMAD3\* \(rs17293443,  \$p = 1.44 \times\$   
232  \$10^{-4}\$ , OR 1.15, 95% CI 1.07-1.23\) loci replicated, but rs12064669 \( \$p=0.88\$ \) was not confirmed  
233 \(Table \[43\]\(#\) and Figure \[S32\]\(#\)\). We also investigated whether any of the proposed 63 candidate  
234 genes<sup>14</sup> was associated with human DZ twinning. In a gene-based test, five genes  
235 demonstrated a nominally significant association \( \$p < 0.05\$ ; \*BMPRIA\* \[MIM: 601299\],  
236 \*BMPR1B\* \[MIM: 603248\], \*IGF1\* \[MIM: 147440\], \*FSHB\* and \*FSHR\* \[MIM: 136435\]\). After  
237 correction for multiple testing, only \*FSHB\* remained significant \(Table \[S76\]\(#\)\).](#)

### **Functional in silico annotation of associated variants**

240 [We explored plausible functional effects of our associated variants using Combined](#)  
241 [Annotation Dependent Depletion \(CADD\)](#),<sup>39</sup> [The \*FSHB\* SNP rs11031006 had a high Phred](#)  
242 [scaled C-score \(22.4\), indicating that it is among the top 1% of SNPs in the human genome](#)  
243 [most likely to have a functional effect. The Phred score for the \*SMAD3\* SNP rs17293443 was](#)  
244 [only 2.71 indicating that it is among the bottom 50% of SNPs in the human genome likely to](#)  
245 [have a functional effect \(Table \[S407\]\(#\)\). Examination of individual constituents of the CADD](#)  
246 [scores showed particularly high conservation-based scores for rs11031006 \(Figure \[S63\]\(#\)\). To](#)  
247 [further investigate possible functional effects we examined data from the ENCODE project](#),<sup>45</sup>

Field Code Changed

Field Code Changed

248 The *FSHB* SNP rs11031006 alters the sequence of 11 protein-binding motifs including that of  
249 the Estrogen receptor alpha, indicating a possible effect on hormonal feedback inhibition  
250 (Table S418). Variant Effect Predictor (VEP)<sup>41</sup> identified rs17293443 as a regulatory region  
251 variant within a promoter flanking region (ENSR00000410126) (Figure S74). SNP  
252 rs17293443 was contained in a *DNase I* hypersensitive site suggesting open chromatin,  
253 although it did not alter any of the transcription factor binding sites present in the promoter  
254 flanking region. Together, these data indicate that rs11031006 and rs17293443 may have  
255 direct functional roles.

#### 256 **SNPs associated with FSH serum level**

257 We analyzed serum FSH measurements from 17,997 genotyped Icelanders and their close  
258 relatives. SNP rs11031006 was significantly associated with higher serum FSH levels ( $p = 2.3$   
259  $\times 10^{-10}$ ), with each G allele conferring an increase in FSH level of about 0.11 SD units (Figure  
260 S54). Notably, the allele (rs11031006-G) conferring the strongest association with FSH levels  
261 in the FSH GWAS is the same allele that conferred the greatest chance of having DZ twins in  
262 our MODZT GWAS. No association was seen between the *SMAD3* signal and serum FSH  
263 levels ( $p = 0.30$ ).

#### 265 **Relative risk of twin birth and polygenic risk score prediction of DZ twinning and** 266 **fertility measures**

267 We estimated that the relative risk of a twin birth, based on approximately 90,000 births in  
268 Iceland between 1950 and 1991, was increased by 18% for each maternal rs11031006-G  
269 allele and by 9% for each rs17293443-C allele (Table S8). A higher polygenic risk score  
270 (PRS) for DZ twinning, calculated based on the results of the DZ twinning GWAS, was  
271 significantly associated with DZ twinning in our independent Icelandic cohort ( $p = 0.001$ )  
272 (Table S7). A higher PRS was also associated with a higher likelihood of having children ( $p =$

273 0.01), higher lifetime number of children ( $p = 0.03$ ), and an earlier age at first child ( $p = 0.02$ )  
274 (Table S98). A re-calculated PRS, excluding the 1 Mb regions surrounding the two replicated  
275 variants, remained associated with DZ twinning ( $p = 0.02$ ) and with the likelihood of having  
276 children ( $p = 0.03$ ). These results reflect the polygenic contribution to the susceptibility to DZ  
277 twinning and its association with greater reproductive ability.

278

### 279 SNPs associated with female reproduction traits

280 Table 24 reports on the two loci robustly implicated in DZ twinning and other reproductive  
281 traits in women. Consistent with its effects on higher circulating FSH levels, the rs11031006-  
282 G allele is also associated with earlier age at menarche,<sup>22; 46</sup> earlier age at first child and  
283 higher total lifetime number of children, lower risk of polycystic ovary syndrome (PCOS),<sup>23</sup>  
284 and earlier age at natural menopause.<sup>24; 47</sup> Also, the DZ twinning SNP rs11031006 is  
285 correlated with a variant (rs10835638, *FSHB*-211G>T) located in the promoter of *FSHB* ( $r^2 =$   
286 0.62) that is associated with timing of breast development in girls.<sup>48</sup> In contrast, the  
287 rs17293443-C allele in *SMAD3* was associated only with a later age at last child (Figure S65).

### 288 ~~Functional in silico annotation of associated variants~~

289 ~~We explored plausible functional effects of our associated variants using Combined~~  
290 ~~Annotation Dependent Depletion (CADD).<sup>38</sup> The *FSHB* SNP rs11031006 had a high Phred~~  
291 ~~scaled C score (22.4), indicating that it is among the top 1% of SNPs in the human genome~~  
292 ~~most likely to have a functional effect. The Phred score for the *SMAD3* SNP rs17293443 was~~  
293 ~~only 2.71 indicating that it is among the bottom 50% of SNPs in the human genome likely to~~  
294 ~~have a functional effect (Table S10). Examination of individual constituents of the CADD~~  
295 ~~scores showed particularly high conservation based scores for rs11031006 (Figure S6). To~~  
296 ~~further investigate possible functional effects we examined data from the ENCODE project.<sup>44</sup>~~  
297 ~~The *FSHB* SNP rs11031006 alters the sequence of 11 protein binding motifs including that of~~

Field Code Changed

Field Code Changed

298 ~~the Estrogen receptor alpha, indicating a possible effect on hormonal feedback inhibition~~  
299 ~~(Table S11). Variant Effect Predictor (VEP)<sup>40</sup> identified rs17293443 as a regulatory region~~  
300 ~~variant within a promoter flanking region (ENSR00000410126) (Figure S7). SNP rs17293443~~  
301 ~~was contained in a DNase I hypersensitive site suggesting open chromatin, although it did not~~  
302 ~~alter any of the transcription factor binding sites present in the promoter flanking region.~~  
303 ~~Together, these data indicate that rs11031006 and rs17293443 may have direct functional~~  
304 ~~roles.~~

## 305 Discussion

306 Here we report the [first](#) compelling evidence that sequence variation at the *FSHB* and  
307 *SMAD3* loci increases the odds of DZ twinning. A number of studies in mothers of DZ twins,  
308 but not all,<sup>49</sup> have found higher FSH levels responsible for multiple follicle growth.<sup>50</sup> The  
309 associations of *FSHB* rs11031006-G with earlier ages at breast development, menarche,  
310 menopause, first child, and higher lifetime parity indicates that this locus plays an important  
311 role in multiple reproductive aspects. Female carriers of rs11031006-G likely may have a  
312 more advanced depletion of the ovarian follicular pool and hence would have an increased  
313 risk of premature ovarian failure (POF, [MIM: 612964]). Indeed advanced ovarian aging is a  
314 recognized feature of familial DZ twinning, with reported lower levels of anti-Mullerian  
315 Hormone (AMH) a marker of lower ovarian primordial follicular reserve.<sup>51</sup> The rs17293443-  
316 C allele in *SMAD3* also increases chances of DZ twinning, but this effect appears independent  
317 of circulating FSH levels.

318 Of the 63 suggested candidate genes for twinning, only *FSHB* was associated in gene-  
319 based tests [after correcting for multiple testing](#). Emerging data in human and non-human  
320 primates suggest that mechanisms underlying multiple ovulation may differ among species,  
321 explaining why in some species twinning is accompanied by unique evolutionary adaptations  
322 enabling offspring's survival, such as the marmoset diminutive fetal size in a simplex uterus,



323 and subsequent alloparenting.<sup>14</sup> Conversely, in humans, multiple gestations remain an  
324 independent risk factor for preterm birth, pregnancy loss, and fetal growth restriction. Thus  
325 loci common to species and strains with higher rates of DZ twinning will not necessarily be  
326 shared, as the rate, complications, and future reproductive fitness of those twin gestations  
327 differ.

328         The third genome-wide hit from the discovery was not replicated in Iceland. SNP  
329 rs120644669 is located 149kb from the angiotensinogen (*AGT*, [MIM: 106150]), which  
330 influences ovulatory capacity in mice,<sup>52</sup> and 89kb from component of oligomeric golgi  
331 complex 2 (*COG2*) affecting protein glycosilation, which regulates the biological activity of  
332 the pituitary gonadotrophins.<sup>53</sup>

333         Genetic variants near *FSHB* (rs11031005 and rs11031002, which are highly correlated  
334 with rs11031006) are reportedly associated not only with higher serum FSH, but also lower  
335 LH levels.<sup>54</sup> This agrees with the known response of the gonadotrophic cell to a high  
336 frequency hypothalamic pulsatile GnRH signal that reciprocally controls secretion of both  
337 hormones.<sup>55</sup> Furthermore, under normal conditions suppression of FSH in the early follicular  
338 phase and higher LH levels in late phase typically favor mono-ovulation in the human.<sup>56</sup> In a  
339 study aiming to identify genetic predictors for IVF success or IVF-controlled ovarian  
340 stimulation (COS), rs611246 located in *FSHB* ( $r^2 = 0.3$  with rs11031006), was reported  
341 significantly associated with measured early follicular phase FSH values and also with the  
342 probability of clinical pregnancy, suggesting that these genetic variants are potential predictor  
343 candidates that could be considered in clinical ovarian reserve and function assessment in  
344 assisted reproduction.<sup>57</sup>

345         A recent linkage study in cattle reported only one strong signal ( $p < 1 \times 10^{-28}$ ) for  
346 ovulation rate in a region spanning *SMAD3*, *SMAD6* (MIM: 602931) and *IQCH* (MIM:  
347 612523).<sup>58</sup> *SMAD3* encodes one of a family of proteins that function as signal transducers and

348 transcriptional modulators that mediate multiple signaling pathways. Observations in mice  
349 have established an essential role for Smad3 in mediating TGFbeta and activin signals in the  
350 ovarian granulosa cell and also in the pituitary<sup>59</sup> to maintain a favorable environment for  
351 oocyte maturation.<sup>60</sup> Smad3 is strongly expressed in the human ovary, where it promotes  
352 granulosa cell proliferation and steroidogenesis possibly by upregulating gonadotrophin  
353 receptor signaling pathways.<sup>61</sup> Thus, sequence variation in *SMAD3* may increase chance of  
354 DZ twinning by increasing responsiveness to FSH. Understanding the role of *SMAD3* will  
355 offer novel opportunities to optimize responsiveness and minimize risk among assisted  
356 reproduction technology (ART) recipients for example through adjustment of hormonal  
357 stimulation and thus contributes to prevention of life-threatening ovarian hyper stimulation  
358 syndrome in hyper responding female carriers of the rs17293443-C allele and conversely  
359 prevention of a poor response in [patients-individuals](#) with allelic variants that lead to a poor  
360 response.

361 The potential applications of this work in reproductive medicine are multifold. Firstly,  
362 it reveals a well-defined set of loci for DZ twinning in the general population. Secondly,  
363 twinning is associated with common perinatal morbidities such as preterm birth, discordant  
364 twin growth, latter prenatal asymmetric intrauterine growth restriction, and placental  
365 abruption. Multiple gestations are also related to a higher prevalence of maternal morbidities  
366 such as preeclampsia, postpartum hemorrhage, and ensuing complications. By understanding  
367 the genetic basis of DZ twinning, we concomitantly identify loci conferring susceptibility (or  
368 conversely resistance) to these prevalent perinatal comorbidities. The involvement of *SMAD3*  
369 is of relevance in the light of a possible phenotype in male DZ twins namely the repeatedly  
370 reported more frequent occurrence of testicular seminoma, a gonadal tumor in which the  
371 mitogenic cyclin D2 is overexpressed.<sup>62; 63</sup> In animal experimental studies knockout of  
372 *SMAD3* significantly attenuates cyclin D2 and tumor proliferation.<sup>64</sup> This indicates to the

373 likely clinical potential of *SMAD3* stretching beyond that of fertility physiology and  
374 treatment.

375 This study ~~The sequence variants found to influence spontaneous DZ twinning and~~  
376 ~~their relationship with other fertility related measures,~~ provides important insights into  
377 ovarian functioning and the control of natural multiple follicle growth and reproductive aging.  
378 This has important implications for fertility, including improved outcome prediction and  
379 novel avenues of fertility treatment. Other strengths include the rigorous phenotype inclusion  
380 of mothers of DZ twins with a documented history of spontaneous DZ twinning. It is worth  
381 mentioning that analyses without excluding mothers who conceived their twins with hormone  
382 induction of multiple ovulation or other ART, did not yield to any genome-wide significant  
383 results (results not shown). We thus recommend twins registries collect data on mode of  
384 pregnancy of twins. There are also some limitations. The current effort focused on unraveling  
385 the genetic basis of DZ twinning in European-ancestry populations only. However, the  
386 highest incidence of DZ twins was reported in the Nigerian population and some other  
387 countries from Africa. Next steps in unraveling the genetic cause of DZ twinning need to  
388 include mothers of DZ twins originating from these regions, and if possible also from regions  
389 where DZ twinning is a rare trait, such as Japan<sup>2</sup>.

390 In summary, we identified *FSHB* and the ~~novel~~-*SMAD3* locus as maternal  
391 susceptibility loci for DZ twinning. These loci are also significantly and specifically  
392 associated with several other aspects of reproductive capacity and health.

393

394

395

396

397

398

399

## Supplemental Data

Supplemental data include ~~seven~~six figures and ~~four~~eight tables

## Acknowledgments

400 ~~A list of support provided to individual studies appears in supplemental data.~~ Support for the  
401 Netherlands Twin Register was obtained from the Netherlands Organization for Scientific  
402 Research (NWO) and The Netherlands Organisation for Health Research and Development  
403 (ZonMW) grants, 904-61-193,480-04-004, 400-05-717, Addiction-31160008, 911-09-032,  
404 Spinozapremie 56-464-14192, Biobanking and Biomolecular Resources Research  
405 Infrastructure (BBMRI –NL, 184.021.007); the European Research Council (ERC-230374  
406 and ERC-284167); Rutgers University Cell and DNA Repository (NIMH U24 MH068457-  
407 06), the Avera Institute, Sioux Falls, South Dakota (USA) and the National Institutes of  
408 Health (NIH R01 HD042157-01A1). Part of the genotyping was funded by the Genetic  
409 Association Information Network (GAIN) of the Foundation for the National Institutes of  
410 Health and Grand Opportunity grants 1RC2 MH089951). We acknowledge support from VU  
411 Amsterdam and the Institute for Health and Care Research (EMGO+). The Berghofer Medical  
412 Research Institute (QIMR) study was supported by grants from the National Health and  
413 Medical Research Council (NHMRC) of Australia (241944, 339462, 389927, 389875,  
414 389891, 389892, 389938, 443036, 442915, 442981, 496610, 496739, 552485, 552498,  
415 1050208, 1075175). Dale R. Nyholt was supported by the Australian Research Council  
416 (ARC) Future Fellowship (FT0991022), NHMRC Research Fellowship (APP0613674)  
417 Schemes and by the Visiting Professors Programme (VPP) of the Royal Netherlands

418 [Academy of Arts and Sciences \(KNAW\). Allan F. McRae was supported by an NRMRC](#)  
419 [Career Development Fellowship \(APP1083656\). Grant W. Montgomery was supported by](#)  
420 [NIH grant \(HD042157, a collaborative study of the genetics of DZ twinning\) and NHMRC](#)  
421 [Fellowship \(GNT1078399\). The Minnesota Center for Twin and Family Research \(MCTFR\)](#)  
422 [was supported in part by USPHS Grants from the National Institute on Alcohol Abuse and](#)  
423 [Alcoholism \(AA09367 and AA11886\), and the National Institute on Drug Abuse \(DA05147,](#)  
424 [DA13240, and DA024417\).](#)

425 [We would like to thank also 23andMe and 23andMe's consented research participants for](#)  
426 [contributing data on age at menarche for the FSHB gene locus and the Twinning Gwas](#)  
427 [Consortium \(TGC\) co-authors from: Finland \(Anu Loukola, Juho Wedenoja, Emmi Tikkanen,](#)  
428 [Beenish Qaiser\), Sweden \(Nancy Pedersen, Andrea Ganna\), United kingdom King's College](#)  
429 [London \(Department of Twin Research & Genetic Epidemiology: Pirro Hysi, Massimo](#)  
430 [Mangino\), Institute of Psychiatry, Psychology & Neuroscience, Medical Research Council](#)  
431 [Social, Genetic and Developmental Psychiatry Centre \(Eva Krapohl, Andrew McMillan\).](#)

S.S, R.P.K, H.S and K.S are employees of deCODE Genetics/Amgen. The other authors declare no competing financial interests.

#### Web Resources

1000GenomesProject, <ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/>

CADD, <http://cadd.gs.washington.edu/>

HaploReg, <http://www.broadinstitute.org/mammals/haploreg/haploreg.php>

Variant Effect Predictor (VEP), <http://www.ensembl.org/info/docs/tools/vep/index.html>

Knowledge-based mining system for Genome-wide Genetic studies (KGG),

<http://grass.cgs.hku.hk/limx/kgg/>

ENCODE, <https://genome.ucsc.edu/ENCODE/>

OMIM, <http://www.omim.org/>

**LDpred**, [https://bitbucket.org/bjarni\\_vilhjalmsson/ldpred](https://bitbucket.org/bjarni_vilhjalmsson/ldpred)

**MACH**, <http://www.sph.umich.edu/csg/abecasis/MACH/>

**Minimac**, <http://genome.sph.umich.edu/wiki/Minimac>

**Beagle**, <https://faculty.washington.edu/browning/beagle/b3.html>

**PLINK**, <http://pngu.mgh.harvard.edu/~purcell/plink/>

**LocusZoom**, <http://csg.sph.umich.edu/locuszoom/>

## References

- 432 1. Bulmer, M.G. (1970). The biology of twinning in man.(Oxford,: Clarendon).
- 433 2. Hall, J.G. (2003). Twinning. *Lancet* 362, 735-743.
- 434 3. Hoekstra, C., Zhao, Z.Z., Lambalk, C.B., Willemsen, G., Martin, N.G., Boomsma, D.I., and  
435 Montgomery, G.W. (2008). Dizygotic twinning. *Hum Reprod Update* 14, 37-47.
- 436 4. Smits, J., and Monden, C. (2011). Twinning across the Developing World. *PLoS One* 6,  
437 e25239.
- 438 5. Kulkarni, A.D., Jamieson, D.J., Jones, H.W., Jr., Kissin, D.M., Gallo, M.F., Macaluso, M.,  
439 and Adashi, E.Y. (2013). Fertility treatments and multiple births in the United States.  
440 *N Engl J Med* 369, 2218-2225.
- 441 6. Fauser, B.C., Devroey, P., and Macklon, N.S. (2005). Multiple birth resulting from ovarian  
442 stimulation for subfertility treatment. *Lancet* 365, 1807-1816.
- 443 7. Chambers, G.M., Hoang, V.P., Lee, E., Hansen, M., Sullivan, E.A., Bower, C., and  
444 Chapman, M. (2014). Hospital costs of multiple-birth and singleton-birth children  
445 during the first 5 years of life and the role of assisted reproductive technology. *JAMA*  
446 *Pediatr* 168, 1045-1053.
- 447 8. van Heesch, M.M., Evers, J.L., van der Hoeven, M.A., Dumoulin, J.C., van Beijsterveldt,  
448 C.E., Bonsel, G.J., Dykgraaf, R.H., van Goudoever, J.B., Koopman-Esseboom, C.,  
449 Nelen, W.L., et al. (2015). Hospital costs during the first 5 years of life for multiples  
450 compared with singletons born after IVF or ICSI. *Hum Reprod* 30, 1481-1490.
- 451 9. Hoekstra, C., Willemsen, G., van Beijsterveldt, C.E., Lambalk, C.B., Montgomery, G.W.,  
452 and Boomsma, D.I. (2010). Body composition, smoking, and spontaneous dizygotic  
453 twinning. *Fertil Steril* 93, 885-893.
- 454 10. Eriksson, A.W., Bressers, W.M., Kostense, P.J., Pitkanen, K.J., Mielke, J.H., Jorde, L.B.,  
455 Tas, R.F., and Fellman, J.O. (1988). Twinning rate in Scandinavia, Germany and The  
456 Netherlands during years of privation. *Acta Genet Med Gemellol (Roma)* 37, 277-297.
- 457 11. White, C., and Wyshak, G. (1964). Inheritance in Human Dizygotic Twinning. *N Engl J*  
458 *Med* 271, 1003-1005.
- 459 12. Moore, R.K., Erickson, G.F., and Shimasaki, S. (2004). Are BMP-15 and GDF-9 primary  
460 determinants of ovulation quota in mammals? *Trends Endocrinol Metab* 15, 356-361.

- 461 13. (2014). The common marmoset genome provides insight into primate biology and  
462 evolution. *Nat Genet* 46, 850-857.
- 463 14. Harris, R.A., Tardif, S.D., Vinar, T., Wildman, D.E., Rutherford, J.N., Rogers, J., Worley,  
464 K.C., and Aagaard, K.M. (2014). Evolutionary genetics and implications of small size  
465 and twinning in callitrichine primates. *Proc Natl Acad Sci U S A* 111, 1467-1472.
- 466 15. Lambalk, C.B. (2001). Is there a role for follicle-stimulating-hormone receptor in familial  
467 dizygotic twinning? *Lancet* 357, 735-736.
- 468 16. Duffy, D., Montgomery, G., Treloar, S., Birley, A., Kirk, K., Boomsma, D., Beem, L., de  
469 Geus, E., Slagboom, E., Knighton, J., et al. (2001). IBD sharing around the PPARG  
470 locus is not increased in dizygotic twins or their mothers. *Nat Genet* 28, 315.
- 471 17. Painter, J.N., Willemsen, G., Nyholt, D., Hoekstra, C., Duffy, D.L., Henders, A.K.,  
472 Wallace, L., Healey, S., Cannon-Albright, L.A., Skolnick, M., et al. (2010). A genome  
473 wide linkage scan for dizygotic twinning in 525 families of mothers of dizygotic  
474 twins. *Hum Reprod* 25, 1569-1580.
- 475 18. Palmer, J.S., Zhao, Z.Z., Hoekstra, C., Hayward, N.K., Webb, P.M., Whiteman, D.C.,  
476 Martin, N.G., Boomsma, D.I., Duffy, D.L., and Montgomery, G.W. (2006). Novel  
477 variants in growth differentiation factor 9 in mothers of dizygotic twins. *J Clin*  
478 *Endocrinol Metab* 91, 4713-4716.
- 479 19. Luong, H.T., Chaplin, J., McRae, A.F., Medland, S.E., Willemsen, G., Nyholt, D.R.,  
480 Henders, A.K., Hoekstra, C., Duffy, D.L., Martin, N.G., et al. (2011). Variation in  
481 BMP1B, TGFRB1 and BMP2 and control of dizygotic twinning. *Twin Res Hum*  
482 *Genet* 14, 408-416.
- 483 20. Tong, S., Caddy, D., and Short, R.V. (1997). Use of dizygotic to monozygotic twinning  
484 ratio as a measure of fertility. *Lancet* 349, 843-845.
- 485 21. Day, F.R., Bulik-Sullivan, B., Hinds, D.A., Finucane, H.K., Murabito, J.M., Tung, J.Y.,  
486 Ong, K.K., and Perry, J.R. (2015). Shared genetic aetiology of puberty timing between  
487 sexes and with health-related outcomes. *Nat Commun* 6, 8842.
- 488 22. Perry, J.R., Day, F., Elks, C.E., Sulem, P., Thompson, D.J., Ferreira, T., He, C., Chasman,  
489 D.I., Esko, T., Thorleifsson, G., et al. (2014). Parent-of-origin-specific allelic  
490 associations among 106 genomic loci for age at menarche. *Nature* 514, 92-97.
- 491 23. Day, F.R., Hinds, D.A., Tung, J.Y., Stolk, L., Styrkarsdottir, U., Saxena, R., Bjornnes, A.,  
492 Broer, L., Dunger, D.B., Halldorsson, B.V., et al. (2015). Causal mechanisms and  
493 balancing selection inferred from genetic associations with polycystic ovary  
494 syndrome. *Nat Commun* 6, 8464.
- 495 24. Day, F.R., Ruth, K.S., Thompson, D.J., Lunetta, K.L., Pervjakova, N., Chasman, D.I.,  
496 Stolk, L., Finucane, H.K., Sulem, P., Bulik-Sullivan, B., et al. (2015). Large-scale  
497 genomic analyses link reproductive aging to hypothalamic signaling, breast cancer  
498 susceptibility and BRCA1-mediated DNA repair. *Nat Genet* 47, 1294-1303.
- 499 25. Boomsma, D.I., de Geus, E.J., Vink, J.M., Stubbe, J.H., Distel, M.A., Hottenga, J.J.,  
500 Posthuma, D., van Beijsterveldt, T.C., Hudziak, J.J., Bartels, M., et al. (2006).  
501 Netherlands Twin Register: from twins to twin families. *Twin research and human*  
502 *genetics : the official journal of the International Society for Twin Studies* 9, 849-857.
- 503 26. Willemsen, G., de Geus, E.J., Bartels, M., van Beijsterveldt, C.E., Brooks, A.I., Estourgie-  
504 van Burk, G.F., Fugman, D.A., Hoekstra, C., Hottenga, J.J., Kluff, K., et al. (2010).

- 505 The Netherlands Twin Register biobank: a resource for genetic epidemiological  
506 studies. *Twin Res Hum Genet* 13, 231-245.
- 507 27. van Beijsterveldt, C.E., Groen-Blokhuis, M., Hottenga, J.J., Franic, S., Hudziak, J.J.,  
508 Lamb, D., Huppertz, C., de Zeeuw, E., Nivard, M., Schutte, N., et al. (2013). The  
509 Young Netherlands Twin Register (YNTR): longitudinal twin and family studies in  
510 over 70,000 children. *Twin Res Hum Genet* 16, 252-267.
- 511 28. Willemsen, G., Vink, J.M., Abdellaoui, A., den Braber, A., van Beek, J.H., Draisma,  
512 H.H., van Dongen, J., van 't Ent, D., Geels, L.M., van Lien, R., et al. (2013). The  
513 Adult Netherlands Twin Register: twenty-five years of survey and biological data  
514 collection. *Twin Res Hum Genet* 16, 271-281.
- 515 29. Penninx, B.W., Beekman, A.T., Smit, J.H., Zitman, F.G., Nolen, W.A., Spinhoven, P.,  
516 Cuijpers, P., De Jong, P.J., Van Marwijk, H.W., Assendelft, W.J., et al. (2008). The  
517 Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and  
518 methods. *International journal of methods in psychiatric research* 17, 121-140.
- 519 30. van Beijsterveldt, C.E., Hoekstra, C., Schats, R., Montgomery, G.W., Willemsen, G., and  
520 Boomsma, D.I. (2008). Mode of conception of twin pregnancies: willingness to reply  
521 to survey items and comparison of survey data to hospital records. *Twin Res Hum  
522 Genet* 11, 349-351.
- 523 31. Miller, M.B., Basu, S., Cunningham, J., Eskin, E., Malone, S.M., Oetting, W.S., Schork,  
524 N., Sul, J.H., Iacono, W.G., and McGue, M. (2012). The Minnesota Center for Twin  
525 and Family Research genome-wide association study. *Twin Res Hum Genet* 15, 767-  
526 774.
- 527 32. Iacono, W.G., Carlson, S.R., Taylor, J., Elkins, I.J., and McGue, M. (1999). Behavioral  
528 disinhibition and the development of substance-use disorders: findings from the  
529 Minnesota Twin Family Study. *Dev Psychopathol* 11, 869-900.
- 530 33. Rogers, W.H. (1993). Regression standard errors in clustered samples. *Stata Technical  
531 Bulletin* 13, 19-23.
- 532 34. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller,  
533 J., Sklar, P., de Bakker, P.I., Daly, M.J., et al. (2007). PLINK: a tool set for whole-  
534 genome association and population-based linkage analyses. *Am J Hum Genet* 81, 559-  
535 575.
- 536 35. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis  
537 of genomewide association scans. *Bioinformatics* 26, 2190-2191.
- 538 36. Gudbjartsson, D.F., Helgason, H., Gudjonsson, S.A., Zink, F., Oddson, A., Gylfason, A.,  
539 Besenbacher, S., Magnusson, G., Halldorsson, B.V., Hjartarson, E., et al. (2015).  
540 Large-scale whole-genome sequencing of the Icelandic population. *Nat Genet* 47, 435-  
541 444.
- 542 37. Devlin, B., and Roeder, K. (1999). Genomic control for association studies. *Biometrics*  
543 55, 997-1004.
- 544 38. Fisher, R.A. (1925). *Statistical methods for research workers.* (Edinburgh, London,: Oliver  
545 and Boyd).
- 546 39. Kircher, M., Witten, D.M., Jain, P., O'Roak, B.J., Cooper, G.M., and Shendure, J. (2014).  
547 A general framework for estimating the relative pathogenicity of human genetic  
548 variants. *Nat Genet* 46, 310-315.



- 549 40. Ward, L.D., and Kellis, M. (2012). HaploReg: a resource for exploring chromatin states,  
550 conservation, and regulatory motif alterations within sets of genetically linked  
551 variants. *Nucleic Acids Res* 40, D930-934.
- 552 41. McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., and Cunningham, F. (2010).  
553 Deriving the consequences of genomic variants with the Ensembl API and SNP Effect  
554 Predictor. *Bioinformatics* 26, 2069-2070.
- 555 42. Li, M.X., Kwan, J.S., and Sham, P.C. (2012). HYST: a hybrid set-based test for genome-  
556 wide association studies, with application to protein-protein interaction-based  
557 association analysis. *Am J Hum Genet* 91, 478-488.
- 558 43. Li, M.X., Gui, H.S., Kwan, J.S., and Sham, P.C. (2011). GATES: a rapid and powerful  
559 gene-based association test using extended Simes procedure. *Am J Hum Genet* 88,  
560 283-293.
- 561 44. Vilhjalmsón, B.J., Yang, J., Finucane, H.K., Gusev, A., Lindstrom, S., Ripke, S.,  
562 Genovese, G., Loh, P.R., Bhatia, G., Do, R., et al. (2015). Modeling Linkage  
563 Disequilibrium Increases Accuracy of Polygenic Risk Scores. *Am J Hum Genet* 97,  
564 576-592.
- 565 45. (2012). An integrated encyclopedia of DNA elements in the human genome. *Nature* 489,  
566 57-74.
- 567 46. Lunetta, K.L., Day, F.R., Sulem, P., Ruth, K.S., Tung, J.Y., Hinds, D.A., Esko, T., Elks,  
568 C.E., Altmaier, E., He, C., et al. (2015). Rare coding variants and X-linked loci  
569 associated with age at menarche. *Nat Commun* 6, 7756.
- 570 47. Stolk, L., Perry, J.R., Chasman, D.I., He, C., Mangino, M., Sulem, P., Barbalic, M., Broer,  
571 L., Byrne, E.M., Ernst, F., et al. (2012). Meta-analyses identify 13 loci associated with  
572 age at menopause and highlight DNA repair and immune pathways. *Nat Genet* 44,  
573 260-268.
- 574 48. Hagen, C.P., Sorensen, K., Aksglaede, L., Mouritsen, A., Mieritz, M.G., Tinggaard, J.,  
575 Wohlfart-Veje, C., Petersen, J.H., Main, K.M., Rajpert-De Meyts, E., et al. (2014).  
576 Pubertal onset in girls is strongly influenced by genetic variation affecting FSH action.  
577 *Sci Rep* 4, 6412.
- 578 49. Gilfillan, C.P., Robertson, D.M., Burger, H.G., Leoni, M.A., Hurley, V.A., and Martin,  
579 N.G. (1996). The control of ovulation in mothers of dizygotic twins. *J Clin Endocrinol*  
580 *Metab* 81, 1557-1562.
- 581 50. Lambalk, C.B., Boomsma, D.I., De Boer, L., De Koning, C.H., Schoute, E., Popp-  
582 Snijders, C., and Schoemaker, J. (1998). Increased levels and pulsatility of follicle-  
583 stimulating hormone in mothers of hereditary dizygotic twins. *J Clin Endocrinol*  
584 *Metab* 83, 481-486.
- 585 51. Van der Stroom, E.M., Konig, T.E., Vink, J.M., Boomsma, D.I., and Lambalk, C.B.  
586 (2013). Ovarian reserve and anti-Mullerian hormone (AMH) in mothers of dizygotic  
587 twins. *Twin Res Hum Genet* 16, 634-638.
- 588 52. Hefler, L.A., and Gregg, A.R. (2001). Influence of the angiotensinogen gene on the  
589 ovulatory capacity of mice. *Fertil Steril* 75, 1206-1211.
- 590 53. Wide, L., and Eriksson, K. (2013). Dynamic changes in glycosylation and glycan  
591 composition of serum FSH and LH during natural ovarian stimulation. *Ups J Med Sci*  
592 118, 153-164.

- 593 54. Ruth, K.S., Campbell, P.J., Chew, S., Lim, E.M., Hadlow, N., Stuckey, B.G., Brown, S.J.,  
594 Feenstra, B., Joseph, J., Surdulescu, G.L., et al. (2015). Genome-wide association  
595 study with 1000 genomes imputation identifies signals for nine sex hormone-related  
596 phenotypes. *Eur J Hum Genet*.
- 597 55. Magill, J.C., Ciccone, N.A., and Kaiser, U.B. (2013). A mathematical model of pulse-  
598 coded hormone signal responses in pituitary gonadotroph cells. *Math Biosci* 246, 38-  
599 46.
- 600 56. Hillier, S.G. (2009). Paracrine support of ovarian stimulation. *Mol Hum Reprod* 15, 843-  
601 850.
- 602 57. Laisk-Podar, T., Kaart, T., Peters, M., and Salumets, A. (2015). Genetic variants  
603 associated with female reproductive ageing - potential markers for assessing ovarian  
604 function and ovarian stimulation outcome. *Reprod Biomed Online*.
- 605 58. Kirkpatrick, B.W., and Morris, C.A. (2015). A Major Gene for Bovine Ovulation Rate.  
606 *PLoS One* 10, e0129025.
- 607 59. Bernard, D.J. (2004). Both SMAD2 and SMAD3 mediate activin-stimulated expression of  
608 the follicle-stimulating hormone beta subunit in mouse gonadotrope cells. *Mol*  
609 *Endocrinol* 18, 606-623.
- 610 60. Gong, X., and McGee, E.A. (2009). Smad3 is required for normal follicular follicle-  
611 stimulating hormone responsiveness in the mouse. *Biol Reprod* 81, 730-738.
- 612 61. Liu, Y., Chen, X., Xue, X., Shen, C., Shi, C., Dong, J., Zhang, H., Liang, R., Li, S., and  
613 Xu, J. (2014). Effects of Smad3 on the proliferation and steroidogenesis in human  
614 ovarian luteinized granulosa cells. *IUBMB Life* 66, 424-437.
- 615 62. Lambalk, C.B., and Boomsma, D.I. (1998). Twinning, cancer, and genetics. *Lancet* 351,  
616 909-910.
- 617 63. Swerdlow, A.J., De Stavola, B.L., Swanwick, M.A., and Maconochie, N.E. (1997). Risks  
618 of breast and testicular cancers in young adult twins in England and Wales: evidence  
619 on prenatal and genetic aetiology. *Lancet* 350, 1723-1728.
- 620 64. Looyenga, B.D., and Hammer, G.D. (2007). Genetic removal of Smad3 from inhibin-null  
621 mice attenuates tumor progression by uncoupling extracellular mitogenic signals from  
622 the cell cycle machinery. *Mol Endocrinol* 21, 2440-2457.
- 623

## **Figures titles and legends**

Figure 1. Manhattan Plot for the genome-wide association meta-analysis of mothers of dizygotic twins. SNPs are plotted on the *x*-axis according to their position on each chromosome against the significance of the association on the *y*-axis (shown as  $-\log_{10} p$

values). The dotted red line denotes  $p=5\times 10^{-8}$  statistical significance. The arrows point to the chromosomal region that reached genome-wide significance level.

[Figure 2. Forest plots depicting risk allele odds ratio \(OR\) estimates at \(A\) rs11031006 \(near FSHB\), \(B\) rs17293443 \(SMAD3\) and \(C\) rs12064669 from each study, the meta-analysis, deCODE \(replication\) and the overall combined results. Black squares indicate the OR and horizontal lines represent the 95% CIs. The combined results are indicated by the black diamond.](#)

### **Tables titles and legends**

[Table 1. Number of cases and controls included in the meta-analysis and replication; mean maternal age at delivery](#)

[Table 2. Sample characteristics for fertility measures traits](#)

Table [43](#). Genome-wide significant loci in the meta-analysis of mothers of spontaneous DZ twins ( $n = 1,980$ ) and replication ( $n = 3,597$ ) versus screened controls

Table [24](#). Association results for the implicated DZ twinning SNPs in fertility-related measures

**Table 1. Number of cases and controls included in the meta-analysis and replication; mean maternal age at delivery**

<u>Cohort</u>	<u>No. of subjects</u>		<u>Mean maternal age at delivery (SD)</u>
	<u>Cases</u>	<u>Controls</u>	
<u>Netherlands</u>	<u>806</u>	<u>4,535</u>	<u>29.7 (4.1)</u>
<u>Australia</u>	<u>606</u>	<u>6,556</u>	<u>29.8 (4.8)</u>
<u>Minnesota</u>	<u>568</u>	<u>1,862</u>	<u>28.3 (4.5)</u>
<b><u>Total discovery</u></b>	<b><u>1,980</u></b>	<b><u>12,953</u></b>	<b><u>29.3 (4.5)</u></b>
<b><u>Replication</u></b>			
<u>Iceland</u>	<u>3,597 (1,356 genotyped; 2,241 <i>in silico</i>)</u>	<u>297,348 (76,342 genotyped; 221,006 <i>in silico</i>)</u>	<u>30.3 (5.8)</u>

**Table 2. Sample characteristics for measure of fertility**

<u>Traits</u>	<u>Sample size</u>	<u>Mean (SD)</u>
<u>Age at menarche</u>	<u>259,247</u>	<u>±</u>
<u>Age at menopause</u>	<u>69,360</u>	<u>±</u>
<u>FSH levels</u>	<u>17,997</u>	<u>=</u>
<u>Has children</u>	<u>41,946</u>	<u>0.94<sup>2</sup></u>
<u>Number of children</u>	<u>41,946</u>	<u>2.9 (1.6)</u>
<u>Age at first child</u>	<u>41,946</u>	<u>23.0 (4.7)</u>
<u>Age at last child</u>	<u>41,946</u>	<u>32.1 (5.5)</u>
<u>Average birth interval</u>	<u>41,946</u>	<u>4.7 (2.5)</u>
<u>Polycystic ovary syndrome</u>	<u>5,184 cases / 82,759 controls</u>	<u>±</u>

<sup>1</sup> this is a large meta-analysis of summary statistics and sample mean is not available

<sup>2</sup> fraction with children;

**Table 13. Genome-wide significant loci in the meta-analysis of mothers of spontaneous DZ twins (n=1,980) and replication (n=3,597) versus screened controls**

SNP	Locus	Position <sup>a</sup>	Gene	Annotation	Risk allele	Meta-analysis			Replication			Combined
						RAF	OR (95%CI)	p	RAF	OR (95% CI)	p	p
rs11031006	<i>11p14.1</i>	30226528	<i>FSHB</i>	5' upstream	G	0.85	1.41 (1.29-1.53)	1.54×10 <sup>-9</sup>	0.85	1.14 (1.06-1.22)	3×10 <sup>-3</sup>	1.25×10 <sup>-10</sup>
rs17293443	<i>15q22.33</i>	67437863	<i>SMAD3</i>	Intron	C	0.24	1.27 (1.19-1.35)	1.57×10 <sup>-8</sup>	0.21	1.15 (1.07-1.23)	1.44×10 <sup>-4</sup>	6.29×10 <sup>-11</sup>
rs12064669	<i>1q42.13</i>	230688643		Intergenic	C	0.10	1.43 (1.31-1.55)	1.23×10 <sup>-8</sup>	0.07	1.01 (0.89-1.13)	0.88	2.09×10 <sup>-7</sup>

<sup>a</sup>SNP position according to NCBI Human Genome Build 37; RAF, risk allele frequency; OR, odd ratio; 95% CI, 95% confidence interval

**Table 24.** Association results for the implicated DZ twinning SNPs in fertility-related measures

DZ twinning and fertility-related measure	rs11031006-G allele (near <i>FSHB</i> )			rs17293443-C allele (in <i>SMAD3</i> )		
	Effect	OR (95% CI)/ <u>Beta (95% CI)</u>	p value	Effect	OR (95% CI)/ <u>Beta (95% CI)</u>	p value
DZ twinning <sup>a</sup>	Increase	<u>1.41 (1.29, 1.53)</u>	1.54×10 <sup>-9</sup>	Increase	<u>1.27 (1.19, 1.35)</u>	1.57×10 <sup>-8</sup>
FSH levels ( <u>SD units</u> ) <sup>b</sup>	Increase	<u>0.11 (0.078, 0.15)</u>	2.3×10 <sup>-10</sup>	–	<u>0.016 (-0.014, 0.045)</u>	0.30
Age at menarche ( <u>years</u> ) <sup>c,d</sup>	Earlier	<u>-0.04 (-0.012, 0.011)</u>	8.5×10 <sup>-10</sup>	<del>Earlier</del>	<u>-0.001 (-0.127, 0.010)</u>	0.84
Age at menopause ( <u>years</u> ) <sup>e</sup>	Earlier	<u>-0.2165 (-0.065, 0.052)</u>	8.5×10 <sup>-14</sup>	–	<u>0.009 (-0.048, 0.049)</u>	<u>-0.71</u>
Has children (yes/no) <sup>f</sup>	–	<u>1.07 (0.98, 1.17)</u>	0.12	–	<u>0.96 (0.89, 1.04)</u>	0.34
Number of children <sup>f</sup>	Increase	<u>0.014 (0.00091, 0.27)<sup>h</sup></u>	0.03	–	<u>0.0048 (-0.0062, 0.016)<sup>h</sup></u>	0.39
Age at first child ( <u>years</u> ) <sup>f</sup>	Earlier	<u>-0.20 (-0.31, -0.086)</u>	5.3×10 <sup>-4</sup>	–	<u>0.032 (-0.065, 0.13)</u>	0.51
Age at last child ( <u>years</u> ) <sup>f</sup>	Earlier	<u>-0.097 (-0.21, 0.015)</u>	0.08	Later	<u>0.14 (0.043, 0.24)</u>	4.7×10 <sup>-3</sup>
Average birth interval ( <u>years</u> ) <sup>f</sup>	–	<u>0.015 (-0.037, 0.057)</u>	0.57	–	<u>0.0051 (-0.040, 0.041)</u>	0.82

		<a href="#">0.067</a>			<a href="#">0.050</a>	
PCOS <sup>g</sup>	Decrease	<a href="#">0.90 (0.84, 0.95)</a>	$+2.39 \times 10^{-49}$	-	<a href="#">1.00 (0.96, 1.05)</a>	0.78

<sup>a</sup>MODZT GWAS; <sup>b</sup>deCODE sample of 17,997 individuals with FSH levels; <sup>c,d</sup>[Lunetta et al. and Perry et al. \(ref 21 and 221\) and Perry et al. \(ref 22\)](#); <sup>e</sup>Day et al. (ref [2424](#)) and [Stolk et al. \(ref 25\)](#); <sup>f</sup>deCODE sample of 41,946 women; <sup>g</sup>Polycystic ovary syndrome, [Hayes-Day et al. \(ref 223\)](#); <sup>h</sup>[factor of increase from log-linear model.](#)